1. Delayed-enhancement cardiac magnetic resonance imaging detects disease progression in patients with mitral valve disease and atrial fibrillationCentral MessagePerspective
- Author
-
Tari-Ann Yates, MD, Ramya Vijayakumar, PhD, Martha McGilvray, MD, Ali J. Khiabani, MD, Nicholas Razo, BS, Laurie Sinn, BSN, RN, Matthew R. Schill, MD, Nassir Marrouche, MD, FHRS, Christian Zemlin, PhD, and Ralph J. Damiano, Jr., MD
- Subjects
atrial fibrillation ,mitral valve disease ,delayed-enhancement magnetic resonance imaging ,atrial fibrosis ,mitral regurgitation ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Surgery ,RD1-811 - Abstract
Objectives: The mechanism by which mitral valve (MV) disease leads to atrial fibrillation (AF) remains poorly understood. Delayed-enhancement cardiac magnetic resonance imaging (DE-MRI) has been used to assess left atrial (LA) fibrosis in patients with lone AF before catheter ablation; however, few studies have used DE-MRI to assess MV-induced LA fibrosis in patients with or without AF undergoing MV surgery. Methods: Between March 2018 and September 2022, 38 subjects were enrolled; 15 age-matched controls, 14 patients with lone mitral regurgitation (MR), and 9 patients with MR and AF (MR + AF). Indexed LA volume, total LA wall, and regional LA posterior wall (LAPW) enhancement were defined by the DE-MRI. One-way analysis of variance was performed. Results: LA volume and LA enhancement were associated (r = 0.451, P = .004). LA volume differed significantly between controls (37.1 ± 10.6 mL) and patients with lone MR (71.0 ± 35.9, P = .020 and controls and patients with MR + AF (99.3 ± 47.4, P
- Published
- 2023
- Full Text
- View/download PDF